GEORGIA MEDICAID FEE-FOR-SERVICE  
BIOLOGIC IMMUNOMODULATORS PA SUMMARY

<table>
<thead>
<tr>
<th>Preferred</th>
<th>Non-Preferred</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arcalyst (rilonacept)</td>
<td>Actemra Subcutaneous (tocilizumab)</td>
</tr>
<tr>
<td>Enbrel (etanercept)</td>
<td>Cimzia (certolizumab)</td>
</tr>
<tr>
<td>Humira (adalimumab)</td>
<td>Cosentyx (secukinumab)</td>
</tr>
<tr>
<td>Ilaris (canakinumab)</td>
<td>Dupixent (dupilumab)</td>
</tr>
<tr>
<td>Kevzara (sarilumab)</td>
<td>Enspryng (satralizumab-mwge)</td>
</tr>
<tr>
<td>Taltz (ixekizumab)</td>
<td>Fasenra Pen (benralizumab autoinjector)</td>
</tr>
<tr>
<td>Xeljanz (tofacitinib)</td>
<td>Kineret (anakinra)</td>
</tr>
<tr>
<td>Xeljanz Oral Solution (tofacitinib)</td>
<td>Nucala Pen (mepolizumab autoinjector)</td>
</tr>
<tr>
<td>Xeljanz XR (tofacitinib extended-release)</td>
<td>Olumiant (baricitinib)</td>
</tr>
<tr>
<td></td>
<td>Orence Subcutaneous (abatacept)</td>
</tr>
<tr>
<td></td>
<td>Otezla (apremilast)</td>
</tr>
<tr>
<td></td>
<td>Rezurock (belomosudil)</td>
</tr>
<tr>
<td></td>
<td>Rinvoq (upadacitinib)</td>
</tr>
<tr>
<td></td>
<td>Siliq (brodalumab)</td>
</tr>
<tr>
<td></td>
<td>Simponi (golimumab)</td>
</tr>
<tr>
<td></td>
<td>Stelara (ustekinumab)</td>
</tr>
<tr>
<td></td>
<td>Skyrizi (risankizumab)</td>
</tr>
<tr>
<td></td>
<td>Tremfya (guselkumab)</td>
</tr>
</tbody>
</table>

The drug names above include all available oral or subcutaneous formulations under the same primary name.

**LENGTH OF AUTHORIZATION:** Varies

**NOTES:**

- All preferred and non-preferred products require prior authorization. Intravenous (IV) formulations of the biologic immunomodulators are not covered under Pharmacy Services.
- **The criteria details below are for the outpatient pharmacy program.** If a medication is being administered in a physician’s office or clinic, then the medication must be billed through the DCH physician services program and not the outpatient pharmacy program. Information regarding the physician services program is located at [www.mmis.georgia.gov](http://www.mmis.georgia.gov).

**PA CRITERIA:**

**Actemra Subcutaneous**

- Approvable for members 2 years of age or older with a diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis (PJIA) who have tried methotrexate, Enbrel and Humira for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions or intolerable side effects with methotrexate, Enbrel and Humira.
- Approvable for members 2 years of age or older with a diagnosis of moderately to severely active systemic juvenile idiopathic arthritis (SJIA) who have experienced an inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects with nonsteroidal anti-inflammatories (NSAIDs) and glucocorticosteroids, or members with
severe disease who have experienced an inadequate response, allergy, contraindication, drug-drug interaction or intolerable side effect with Ilaris.

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active rheumatoid arthritis (RA) who have tried methotrexate, alone or in combination with another disease modifying antirheumatic drug (DMARD), and two of the following, Xeljanz, Kevzara, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions or intolerable side effects with methotrexate and two of the following: Xeljanz, Enbrel and Humira.

- Approvable for members 18 years of age or older with a diagnosis of giant cell (temporal) arteritis (GCA) when used in combination with a tapering course of glucocorticoid.

- Approvable for members 18 years of age or older with a diagnosis of active systemic sclerosis-associated interstitial lung disease (SSc-ILD) who have experiences an inadequate response, allergies, contraindications, drug-drug interactions, or intolerable side effects with mycophenolate mofetil and cyclophosphamide or azathioprine.

- Member’s absolute neutrophil count (ANC) must be ≥2000 cells/mm³, platelet count must be ≥100,000 cells/mm³ and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be within normal limits or <1.5 times the upper limit of normal.

**ArcaLy**

- Approvable for members 12 years of age or older with a diagnosis of cryopyrin-associated periodic syndromes (CAPS, including familial cold auto-inflammatory syndrome [FCAS] and Muckle-Wells syndrome [MWS]).

- Approvable for members 10 kg or older with a diagnosis of deficiency of interleukin-1 receptor antagonist (DIRA).

- Approvable for members 12 years of age or older with a diagnosis of recurrent pericarditis (RP) who have experienced an inadequate response, allergies, contraindications, drug-drug interactions, or intolerable side effects with combination therapy with colchicine and nonsteroidal anti-inflammatories (NSAIDs), glucocorticosteroids and/or aspirin.

**Cimzia**

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active Crohn’s disease (CD) who have tried Humira for 3 months and failed to achieve an adequate response, or who have an allergy, contraindication, drug-drug interaction or intolerable side effect with Humira.

- Approvable for members 18 years of age or older with a diagnosis of active ankylosing spondylitis (AS) who have tried two of the following, Taltz, Enbrel and Humira for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with two of the following, Taltz, Enbrel and Humira.

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active rheumatoid arthritis (RA) who have tried two of the following, Xeljanz, Kevzara, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions or intolerable side effects with two of the following, Xeljanz, Kevzara, Enbrel and Humira.

- Approvable for members 18 years of age or older with a diagnosis of active psoriatic arthritis (PsA) who have tried two of the following, Xeljanz, Taltz, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications,
drug-drug interactions, or intolerable side effects with two of the following: Xeljanz, Taltz, Enbrel and Humira.

- Approvable for members 18 years of age or older with a diagnosis of moderate to severe plaque psoriasis (PsO) with ≥10% of body surface area involvement who have tried phototherapy and two of the following, Taltz, Enbrel and Humira for 3 months each and failed to achieve an adequate response, or who are unable to tolerate or try phototherapy due to logistical issues and who have allergies, contraindications, drug-drug interactions or intolerable side effects with two of the following, Taltz, Enbrel and Humira.

- Approvable for members 18 years of age or older with a diagnosis of active non-radiographic axial spondyloarthritis (nr-axSpA) who have objective signs of inflammation confirmed by C-reactive protein (CRP) levels above the upper limit of normal (ULN) or sacroiliitis on magnetic resonance imaging (MRI) and who have tried at least two nonsteroidal antiinflammatory drugs (NSAIDs) at maximally-tolerated doses for at least 4 weeks and failed to achieve an adequate response, or who have an allergy, contraindication, drug-drug interaction or intolerable side effect to NSAIDs.

**Cosentyx**

- Approvable for members 6 years of age or older with a diagnosis of moderate to severe plaque psoriasis (PsO) with ≥10% of body surface area involvement who have tried phototherapy, Taltz and Humira for 3 months each and failed to achieve an adequate response, or who are unable to tolerate or try phototherapy due to logistical issues and who have allergies, contraindications, drug-drug interactions, or intolerable side effects with Humira and Taltz.

- Approvable for members 18 years of age or older with a diagnosis of active ankylosing spondylitis who have tried Taltz, Enbrel and Humira for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with Taltz, Enbrel and Humira.

- Approvable for members 18 years of age or older with a diagnosis of active psoriatic arthritis who have tried Xeljanz, Taltz, Enbrel and Humira and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions or intolerable side effects with Xeljanz, Taltz, Enbrel and Humira.

- Approvable for members 18 years of age or older with a diagnosis of active non-radiographic axial spondyloarthritis (nr-axSpA) who have objective signs of inflammation confirmed by C-reactive protein (CRP) levels above the upper limit of normal (ULN) or sacroiliitis on magnetic resonance imaging (MRI) and who have tried at least two nonsteroidal antiinflammatory drugs (NSAIDs) at maximally-tolerated doses for at least 4 weeks and failed to achieve an adequate response, or who have an allergy, contraindication, drug-drug interaction or intolerable side effect to NSAIDs.

**Dupixent**

- Approvable for members 6 years of age or older with a diagnosis of moderate atopic dermatitis (eczema) with ≥10% of body surface area involvement who have tried medium to very high potency topical corticosteroids and three of the following topical therapies (1) crisaborole (Eucrisa), (2) ruxolitinib (Opzelura) and (3) pimecrolimus (Elidel) or tacrolimus (Protopic) and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions or intolerable side effects with topical corticosteroids and three of the following topical therapies (1) crisaborole (Eucrisa), (2) ruxolitinib (Opzelura) and (3) pimecrolimus (Elidel) or tacrolimus (Protopic).
- Approvable for members 6 years of age or older with a diagnosis of severe atopic dermatitis (eczema) with >10% of body surface area involvement who have tried medium to very high potency topical corticosteroids and topical tacrolimus (Protopic) and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions or intolerable side effects with topical corticosteroids and topical tacrolimus (Protopic).

- Approvable for members 6 years of age or older with a diagnosis of moderate to severe asthma of eosinophilic phenotype (eosinophil count ≥150 cells/mcL) who have tried a medium-to-high dose inhaled corticosteroid with a long-acting beta agonist or other non-corticosteroid controller medication and failed to achieve asthma control and when the medication is being added on to the member’s current maintenance asthma therapy.

- Approvable for members 6 years of age or older with a diagnosis of moderate to severe asthma who are dependent on an oral corticosteroid and who have tried a high dose inhaled corticosteroid with a long-acting beta agonist or other non-corticosteroid controller medication and failed to achieve asthma control and when the medication is being added on to the member’s current maintenance asthma therapy.

- Approvable for members 18 years of age or older with a diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) who have tried oral corticosteroid therapy and failed to achieve an adequate response, or the member is not a candidate for oral corticosteroid therapy and who are currently using an intranasal corticosteroid therapy and failed to achieve an adequate response.

**Enbrel**

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active rheumatoid arthritis when the member has tried methotrexate alone or in combination with another DMARD for 3 months and failed to achieve an adequate response.

- Approvable for members 18 years of age or older with a diagnosis of active psoriatic arthritis when the member has tried a generic DMARD and failed to achieve an adequate response.

- Approvable for members 18 years of age or older with a diagnosis of active ankylosing spondylitis when the member has tried two nonsteroidal anti-inflammatory drugs (NSAIDs) and failed to achieve an adequate response OR when NSAIDs are contraindicated.

- Approvable for members 4 years of age or older with a diagnosis of moderate to severe plaque psoriasis with >10% of body surface area involvement when the member has tried phototherapy for 3 months as well as topical AND systemic therapy and failed to achieve an adequate response.

- Approvable for members 2 years of age or older with a diagnosis of moderately to severely active juvenile idiopathic arthritis (JIA)/juvenile rheumatoid arthritis (JRA) when the member has tried methotrexate for 3 months and failed to achieve an adequate response OR when methotrexate is contraindicated.

**Enspryn**

- Approvable for members 18 years of age or older with a diagnosis of neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive and who have a core clinical characteristic of NMOSD and have experienced at least one relapse in the last 12 months or two relapses in the last 2 years on current therapy.

**Fasenra Pen**

- Approvable for members 12 years of age or older with a diagnosis of severe asthma of eosinophilic phenotype (eosinophil count ≥150 cells/mcL) who have tried a high dose...
inhaled corticosteroid with a long-acting beta agonist or other non-corticosteroid controller medication and failed to achieve asthma control and when the medication is being added on to the member’s current maintenance asthma therapy.

**Humira**

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active rheumatoid arthritis when the member has tried methotrexate alone or in combination with another DMARD for 3 months and failed to achieve an adequate response.
- Approvable for members 6 years of age or older with a diagnosis of moderately to severely active Crohn’s disease when the member has tried conventional therapy (corticosteroids, immunosuppressants, sulfasalazine, mesalamine) and failed to achieve an adequate response.
- Approvable for members 18 years of age or older with a diagnosis of active psoriatic arthritis when the member has tried a generic DMARD and failed to achieve an adequate response.
- Approvable for members 18 years of age or older with a diagnosis of active ankylosing spondylitis when the member has tried two NSAIDs and failed to achieve an adequate response OR when NSAIDs are contraindicated.
- Approvable for members 18 years of age or older with a diagnosis of moderate to severe plaque psoriasis with $\geq 10\%$ of body surface area involvement when the member has tried phototherapy for 3 months as well as topical AND systemic therapy and failed to achieve an adequate response.
- Approvable for members 2 years of age or older with a diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis/juvenile rheumatoid arthritis when the member has tried methotrexate for 3 months and failed to achieve an adequate response OR when methotrexate is contraindicated.
- Approvable for members 5 years of age or older with a diagnosis of moderately to severely active ulcerative colitis (UC) when the member has tried oral or intravenous corticosteroids AND at least one of the following: 6-mercaptopurine or azathioprine and failed to achieve an adequate response.
- Approvable for members 12 years of age or older with a diagnosis of moderate to severe hidradenitis suppurativa (acne inversa) who have tried oral antibiotic therapy and failed to achieve an adequate response.
- Approvable for members 2 years of age or older with a diagnosis of non-infectious intermediate uveitis, posterior uveitis or panuveitis when the member has tried antimetabolite (e.g., azathioprine, methotrexate, mycophenolate mofetil) or calcineurin inhibitor therapy (e.g., cyclosporine, tacrolimus) and failed to achieve an adequate response.

**Ilaris**

- Approvable for members 4 years of age or older with a diagnosis of cryopyrin-associated periodic syndromes (CAPS; includes familial cold auto-inflammatory syndrome [FCAS] and Muckle-Wells syndrome [MWS]).
- Approvable for members 2 years of age or older with a diagnosis of moderately active systemic juvenile idiopathic arthritis (SJIA) who have experienced inadequate response, allergies, contraindications, drug-drug interactions, or intolerable side effects with NSAIDs and glucocorticosteroids.
- Approvable for members 2 years of age or older with a diagnosis of severely active SJIA.
- Approvable for members 2 years of age or older with a diagnosis of tumor necrosis factor receptor (TNF) associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) or familial Mediterranean fever (FMF).

Revised 6/16/2022
- Approvable for members 2 years of age or older with a diagnosis of active Still’s disease (SD), including adult-onset Still’s disease (AOSD), who have tried a glucocorticoid (i.e., prednisone) for 2 months and failed to achieve an adequate response or was unable to lower dose.

**Kevzara**

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active rheumatoid arthritis (RA) who have tried one of the following, Xeljanz, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who have an allergy, contraindication, drug-drug interaction or intolerable side effect with one of the following: Xeljanz, Enbrel and Humira.
- Member’s absolute neutrophil count (ANC) must be $>2000$ cells/mm$^3$, platelet count must be $>150,000$ cells/mm$^3$ and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be within normal limits or <1.5 times the upper limit of normal.

**Kinera**

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active rheumatoid arthritis (RA) who have tried two of the following, Xeljanz, Kevzara, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions or intolerable side effects with two of the following: Xeljanz, Kevzara, Enbrel and Humira.
- Approvable for members with a diagnosis of neonatal-onset multisystem inflammatory disease (NOMID) associated with cryopyrin-associated periodic syndromes (CAPS).
- Approvable for members with a diagnosis of deficiency of interleukin-1 receptor antagonist (DIRA).

**Nucala Pen**

- Approvable for members 6 years of age or older with a diagnosis of severe asthma of eosinophilic phenotype (eosinophil count $>150$ cells/mCL) who have tried a high dose inhaled corticosteroid with a long-acting beta agonist or other non-corticosteroid controller medication and failed to achieve asthma control and have experienced 2 or more exacerbations in the previous 12 months and when the medication is being added on to the member’s current maintenance asthma therapy.
- Approvable for members 18 years of age or older with a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) who have tried glucocorticoid (e.g., prednisone, methylprednisolone, prednisolone) in combination with an immunosuppressant (e.g., cyclophosphamide, azathioprine, methotrexate, leflunomide) for at least 6 months and failed to achieve an adequate response or who have allergies, contraindications, drug-drug interactions or intolerable side effects to glucocorticoids and immunosuppressants.
- Approvable for member 12 years of age or older with a diagnosis of hypereosinophilic syndrome (HES) for at least 6 months without an identifiable non-hematologic secondary cause who have an eosinophil count $>1000$ cells/mCL and who have been on stable HES therapy (e.g., corticosteroid, immunosuppressive and/or cytotoxic therapy) and have experienced 2 or more flares in the previous 12 months.
- Approvable for members 18 years of age or older with a diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) who have tried oral corticosteroid therapy and failed to achieve an adequate response, or the member is not a candidate for oral corticosteroid therapy.

Revised 6/16/2022
therapy and who are currently using an intranasal corticosteroid therapy and failed to achieve an adequate response.

**Olumiant**

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active rheumatoid arthritis who have tried methotrexate, alone or in combination with another DMARD, as well as Xeljanz, Kevzara, Enbrel and Humira for 3 months each and failed to achieve an adequate response or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with Xeljanz, Kevzara, Enbrel and Humira.
- Member’s absolute lymphocyte count (ALC) must be \( \geq 500 \) cells/mm\(^3\), absolute neutrophil count (ANC) must be \( \geq 1000 \) cells/mm\(^3\) and hemoglobin \( \geq 8 \) g/dL.

**Orencia Subcutaneous**

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active rheumatoid arthritis (RA) who have tried methotrexate, alone or in combination with another disease modifying antirheumatic drug (DMARD), and two of the following, Xeljanz, Kevzara, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions or intolerable side effects with two of the following: Xeljanz, Kevzara, Enbrel and Humira.
- Approvable for members 18 years of age or older with a diagnosis of active psoriatic arthritis (PsA) who have tried two of the following, Xeljanz, Taltz, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with two of the following: Xeljanz, Taltz, Enbrel and Humira.
- Approvable for members 2 years of age or older with a diagnosis of moderately to severely active juvenile idiopathic arthritis/juvenile rheumatoid arthritis who have tried Enbrel and Humira for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with Enbrel and Humira.

**Otezla**

- Approvable for members 18 years of age or older with a diagnosis of active psoriatic arthritis when the member has tried at least two preferred DMARDs and failed to achieve an adequate response.
- Approvable for members 18 years of age or older with moderate to severe plaque psoriasis with \( \geq 10\% \) of body surface area involvement who have tried phototherapy for 3 months or who are unable to tolerate or try phototherapy due to logistical issues and who have tried two preferred systemic therapies and failed to achieve an adequate response.
- Approvable for members 18 years of age or older with a diagnosis of at least 2 active oral ulcers associated with Behcet’s disease and when other causes of the oral ulcers have been ruled out.

**Rezurock**

- Approvable for members 12 years of age or older with a diagnosis of chronic graft-versus-host disease (chronic GVHD) who are previous recipient of an allogeneic hematopoietic stem cell transplant and have experienced inadequate response, allergies, contraindications, drug-drug interactions, or intolerable side effects with at least 2 prior lines of systemic therapy.

Revised 6/16/2022
**Rinvoq**

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active rheumatoid arthritis who have tried methotrexate, alone or in combination with another DMARD, as well as Xeljanz, Kevzara, Enbrel and Humira for 3 months each and failed to achieve an adequate response or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with Xeljanz, Kevzara, Enbrel and Humira.
- Approvable for members 18 years of age or older with a diagnosis of active psoriatic arthritis (PsA) who have tried Xeljanz, Taltz, Enbrel and Humira for 3 months each and failed to achieve an adequate response or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with Xeljanz, Taltz, Enbrel and Humira.
- Approvable for members 12 years of age or older with a diagnosis of refractory, moderate atopic dermatitis (AD) with ≥10% of body surface area involvement who have tried medium to very high potency topical corticosteroids, three of the following topical therapies (1) crisaborole (Eucrisa), (2) ruxolitinib (Opzelura) and (3) pimecrolimus (Elidel) or tacrolimus (Protopic), and Dupixent and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions or intolerable side effects with topical corticosteroids, three of the following topical therapies (1) crisaborole (Eucrisa), (2) ruxolitinib (Opzelura) and (3) pimecrolimus (Elidel) or tacrolimus (Protopic), and Dupixent.
- Approvable for members 12 years of age or older with a diagnosis of refractory, severe atopic dermatitis (eczema) with ≥10% of body surface area involvement who have tried medium to very high potency topical corticosteroids, topical tacrolimus (Protopic) and Dupixent and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with topical corticosteroids, topical tacrolimus (Protopic) and Dupixent.
- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active ulcerative colitis (UC) who have tried oral or intravenous corticosteroids and at least one of the following: 6-mercaptopurine or azathioprine and failed to achieve an adequate response and who have tried Humira and Xeljanz for 3 months each and failed to achieve an adequate response, or who have an allergies, contraindications, drug-drug interactions or intolerable side effects with Humira and Xeljanz.
- Approvable for members 18 years of age or older with a diagnosis of active ankylosing spondylitis who have tried Taltz, Enbrel and Humira for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with Taltz, Enbrel and Humira.
- Member’s absolute lymphocyte count (ALC) must be ≥500 cells/mm³, absolute neutrophil count (ANC) must be ≥1000 cells/mm³ and hemoglobin ≥8 g/dL.

**Siliq**

- Approvable for members 18 years of age or older with a diagnosis of moderate to severe plaque psoriasis (PsO) with ≥10% of body surface area involvement who have tried phototherapy, Taltz, Enbrel and Humira for 3 months each and failed to achieve an adequate response, or who are unable to tolerate or try phototherapy due to logistical issues and who have allergies, contraindications, drug-drug interactions, or intolerable side effects with Taltz, Enbrel and Humira.

**Simponi**

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate who have tried two of the
following, Xeljanz, Kevzara, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with methotrexate and two of the following: Xeljanz, Kevzara, Enbrel and Humira.

- Approvable for members 18 years of age or older with a diagnosis of active ankylosing spondylitis who have tried two of the following, Taltz, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with Taltz, Enbrel and Humira.

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active ulcerative colitis who have tried Humira for 3 months each and failed to achieve an adequate response, or who have an allergy, contraindication, drug-drug interaction, or intolerable side effect with Humira.

- Approvable for members 18 years of age or older with a diagnosis of active psoriatic arthritis (PsA) who have tried two of the following, Xeljanz, Taltz, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with two of the following: Xeljanz, Taltz, Enbrel and Humira.

**Skyrizi**

- Approvable for members 18 years of age or older with a diagnosis of moderate to severe plaque psoriasis (PsO) with $\geq 10\%$ of body surface area involvement who have tried phototherapy, Taltz and Humira for 3 months each and failed to achieve an adequate response, or who are unable to tolerate or try phototherapy due to logistical issues and who have allergies, contraindications, drug-drug interactions, or intolerable side effects with Humira and Taltz.

**Stelara**

- Approvable for member 6 years of age or older with a diagnosis of moderate to severe plaque psoriasis with $\geq 10\%$ of body surface area involvement who have tried phototherapy as well as two of the following, Taltz, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who are unable to tolerate or try phototherapy due to logistical issues and who have allergies, contraindications, drug-drug interactions or intolerable side effects with two of the following: Taltz, Enbrel and Humira.

- Approvable for members 18 years of age or older with a diagnosis of active psoriatic arthritis (PsA) who have tried two of the following, Xeljanz, Taltz, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with two of the following: Xeljanz, Taltz, Enbrel and Humira.

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active Crohn’s disease (CD) who have tried Humira for 3 months and failed to achieve an adequate response, or who have an allergy, contraindication, drug-drug interaction, or intolerable side effect with Humira.

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active ulcerative colitis (UC) who have tried oral or intravenous corticosteroids and at least one of the following: 6-mercaptopurine or azathioprine and failed to achieve an adequate response and who have tried Humira for 3 months each and failed to achieve an adequate response, or who have an allergy, contraindication, drug-drug interaction, or intolerable side effect with Humira.
Taltz

- Approvable for members 6-17 years of age or older with a diagnosis of moderate to severe plaque psoriasis (PsO) with \( \geq 10\% \) of body surface area involvement who have tried phototherapy and Enbrel for 3 months each and failed to achieve an adequate response, or who are unable to tolerate or try phototherapy due to logistical issues and who have an allergy, contraindication, drug-drug interaction, or intolerable side effect with Enbrel.

- Approvable for members 18 years of age or older with a diagnosis of moderate to severe plaque psoriasis (PsO) with \( \geq 10\% \) of body surface area involvement who have tried phototherapy and Humira for 3 months each and failed to achieve an adequate response, or who are unable to tolerate or try phototherapy due to logistical issues and who have an allergy, contraindication, drug-drug interaction, or intolerable side effect with Humira.

- Approvable for members 18 years of age or older with a diagnosis of active psoriatic arthritis (PsA) who have tried one of the following, Xeljanz, Enbrel and Humira, for 3 months and failed to achieve an adequate response, or who have an allergy, contraindication, drug-drug interaction or intolerable side effect with one of the following: Xeljanz, Enbrel and Humira.

- Approvable for members 18 years of age or older with a diagnosis of active ankylosing spondylitis (AS) who have tried Enbrel or Humira for 3 months and failed to achieve an adequate response, or who have an allergy, contraindication, drug-drug interaction or intolerable side effect with Enbrel or Humira.

- Approvable for members 18 years of age or older with a diagnosis of active non-radiographic axial spondyloarthritis (nr-axSpA) who have objective signs of inflammation confirmed by C-reactive protein (CRP) levels above the upper limit of normal (ULN) or sacroiliitis on magnetic resonance imaging (MRI) and who have tried at least two nonsteroidal antiinflammatory drugs (NSAIDs) at maximally-tolerated doses for at least 4 weeks and failed to achieve an adequate response, or who have an allergy, contraindication, drug-drug interaction or intolerable side effect to NSAIDs.

Tremfya

- Approvable for members 18 years of age or older with a diagnosis of moderate to severe plaque psoriasis (PsO) with \( \geq 10\% \) of body surface area involvement who have tried phototherapy, Taltz and Humira for 3 months each and failed to achieve an adequate response, or who are unable to tolerate or try phototherapy due to logistical issues and who have an allergy, contraindication, drug-drug interaction, or intolerable side effect with Humira and Taltz.

- Approvable for members 18 years of age or older with a diagnosis of active psoriatic arthritis (PsA) who have tried two of the following, Xeljanz, Taltz, Enbrel and Humira, for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with two of the following: Xeljanz, Taltz, Enbrel and Humira.

Xeljanz and Xeljanz XR

- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active rheumatoid arthritis (RA) who have tried methotrexate alone or in combination with another DMARD for 3 months and failed to achieve an adequate response.

- Approvable for members 18 years of age or older with a diagnosis of active psoriatic arthritis (PsA) who have tried a generic DMARD and failed to achieve an adequate response and who will use concurrent therapy with a nonbiologic DMARD.
- Approvable for members 18 years of age or older with a diagnosis of moderately to severely active ulcerative colitis (UC) who have tried oral or intravenous corticosteroids and at least one of the following: 6-mercaptopurine or azathioprine and failed to achieve an adequate response and who have tried Humira for 3 months each and failed to achieve an adequate response, or who have an allergy, contraindication, drug-drug interaction or intolerable side effect with Humira and when the lowest effective dose for the shortest duration needed to achieve/maintain therapeutic response will be used.
- Approvable for members 2 years of age or older with a diagnosis of active polyarticular course juvenile idiopathic arthritis (pcJIA) who have tried methotrexate for 3 months and failed to achieve an adequate response unless methotrexate is contraindicated.
- Approvable for members 18 years of age or older with a diagnosis of ankylosing spondylitis (AS) who have tried Enbrel or Humira for 3 months each and failed to achieve an adequate response, or who have allergies, contraindications, drug-drug interactions, or intolerable side effects with Enbrel and Humira.
- Member’s absolute lymphocyte count (ALC) must be \( \geq 500 \) cells/mm\(^3\), absolute neutrophil count (ANC) must be \( \geq 1000 \) cells/mm\(^3\) and hemoglobin \( \geq 9 \) g/dL.
- In addition to meeting the criteria above for Xeljanz XR, prescriber must also submit a written letter of medical necessity stating the reasons Xeljanz (regular-release) is not appropriate for the member.

**Xeljanz Oral Solution**

- Approvable for members 2 to 12 years of age with a diagnosis of active polyarticular course juvenile idiopathic arthritis (pcJIA) who have tried methotrexate for 3 months and failed to achieve an adequate response unless methotrexate is contraindicated.
- Approvable for member 13 years of age or older with a diagnosis of active pcJIA who have tried methotrexate for 3 months and failed to achieve an adequate response unless methotrexate is contraindicated and who are unable to swallow solid oral dosage formulations (i.e., tablets) or require dosing that cannot be obtained with the 5 mg tablets.

**EXCEPTIONS:**

- Exceptions to these conditions of coverage are considered through the prior authorization process.
- The Prior Authorization process may be initiated by calling **OptumRx at 1-866-525-5827**.

**PREFERRED DRUG LIST:**

- For online access to the Preferred Drug List (PDL), please go to [http://dch.georgia.gov/preferred-drug-lists](http://dch.georgia.gov/preferred-drug-lists).

**PA AND APPEAL PROCESS:**

- For online access to the PA process, please go to [www.dch.georgia.gov/prior-authorization-process-and-criteria](http://www.dch.georgia.gov/prior-authorization-process-and-criteria) and click on Prior Authorization (PA) Request Process Guide.

**QUANTITY LEVEL LIMITATIONS:**

- For online access to the current Quantity Level Limits (QLL), please go to [www.mmis.georgia.gov/portal](http://www.mmis.georgia.gov/portal), highlight Pharmacy and click on **Other Documents**, then select the most recent quarters QLL list.

Revised 6/16/2022